科笛-B(02487.HK):CU-20401(重組突變膠原酶)治療頦下脂肪堆積II期臨牀試驗完成最後一例受試者入組
格隆匯6月28日丨科笛-B(02487.HK)發佈公吿,集團的潛在1類新藥CU-20401(重組突變膠原酶),用於治療頦下脂肪堆積的II期臨牀試驗完成最後一例受試者入組。
CU-20401是一種重組突變膠原酶,其靶向肥胖、超重或其他與局部脂肪堆積相關的代謝疾病。CU-20401採用創新的作用機制,作為一種膠原酶,可選擇性地作用於附着在脂肪組織上的細胞外基質。經局部注射後,CU-20401通過降解皮下脂肪層中的細胞外基質膠原蛋白,導致脂肪細胞凋亡,預計可有效減少局部脂肪堆積。CU-20401通過技術改進,以較低速率催化膠原蛋白降解,具有温和的催化活性,從而減少野生型膠原酶的副作用,如淤青及疼痛。CU-20401在中國進行的用於治療頦下脂肪堆積的II期臨牀試驗是一項多中心、隨機、雙盲及安慰劑對照試驗,以觀察CU-20401的有效性及安全性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.